1984-25-4

Basic information

• Product Name: 4-BROMO-N-ETHYLBENZENESULPHONAMIDE
• Synonyms: N-ETHYL 4-BROMOBENZENESULFONAMIDE;p-bromo-n-ethyl-benzenesulfonamid;4-BROMO-N-ETHYLBENZENESULPHONAMIDE;4-Bromo-N-ethylbenzenesulphonamide 98%;N-Ethyl-p-bromobenzenesulfonamide;4-Bromo-N-ethylbenzenesulphonamide98%
• CAS NO: 1984-25-4
• Molecular Formula: C₈H₁₀BrNO₂S
• Molecular Weight: 264.14
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 1984-25-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 69-71
• Boiling Point: 342.5 °C at 760 mmHg
• Flash Point: 161 °C
• Appearance: /
• Density: 1.529 g/cm³
• Vapor Pressure: 7.48E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.29±0.50(Predicted)
• CAS DataBase Reference: 4-BROMO-N-ETHYLBENZENESULPHONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-N-ETHYLBENZENESULPHONAMIDE(1984-25-4)
• EPA Substance Registry System: 4-BROMO-N-ETHYLBENZENESULPHONAMIDE(1984-25-4)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 1984-25-4(Hazardous Substances Data)

Usage

General Description

4-Bromo-N-ethylbenzenesulphonamide is a chemical compound that belongs to the family of benzene derivatives. It is an organic compound containing a sulfonamide group, which has a bromine atom attached to the benzene ring and an ethyl group attached to the nitrogen atom. 4-BROMO-N-ETHYLBENZENESULPHONAMIDE is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and agrochemicals. It has also been investigated for its potential use as an antimicrobial and antitumor agent. Overall, 4-Bromo-N-ethylbenzenesulphonamide is a versatile chemical with a wide range of potential applications in different fields.

InChI:InChI=1/C8H10BrNO2S/c1-2-10-13(11,12)8-5-3-7(9)4-6-8/h3-6,10H,2H2,1H3

Upstream product

• 557-66-4 ethanamine hydrochloride 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 75-04-7 ethylamine 

Downstream Products

• 871329-65-6 4-(N-ethylsulfamoyl)phenylboronic acid 
• 936728-18-6 4-bromo-N-ethylbenzenesulfonamide 
• 56059-56-4 N-Ethyl-N-thallium(I)-4-bromphenylsulfonamid 
• 1572928-47-2 benzyl 4-(4-(ethylsulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572927-73-1 4-(2S)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-ethylbenzenesulfonamide 
• 1572927-74-2 4-(2R)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-ethylbenzenesulfonamide 
• 1572928-49-4 tert-butyl (5-((4-(4-(ethylsulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1572928-48-3 N-ethyl-4-(2-(1-propyn-1-yl)-1-piperazinyl)benzenesulfonamide 

Relevant articles and documents

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where gluco

ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; trea